Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Alcon reported Q4 and full-year 2020 financial results, revealing a 2% increase in Q4 sales to $1.9 billion compared to Q4 2019. However, full-year sales fell 8% to $6.8 billion. Q4 diluted EPS was $0.19 with core diluted EPS at $0.41. Full-year diluted losses per share were $1.09, while core diluted EPS was $1.04. The company noted strong recovery in the second half of 2020 following COVID-19 impacts. A proposed dividend of CHF 0.10 per share has been announced, pending shareholder approval in April 2021.
Alcon (SIX/NYSE: ALC) announces the launch of Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) in U.S. stores and online. Approved by the FDA for OTC sales in 2020, this product strengthens Alcon's position in the ocular allergy market, joining the top-selling OTC eye allergy relief brand. Catering to approx. 66 million Americans with ocular allergies, it provides 24-hour relief with just one drop daily. The launch will be supported by extensive advertising campaigns to reach potential users.
Alcon (SIX/NYSE: ALC) has launched the PRECISION1® for Astigmatism, a daily disposable silicone hydrogel contact lens aimed at individuals with astigmatism. This innovative product integrates SMARTSURFACE® technology and features a stable lens-wearing experience with a 99% first fit success rate. The company estimates that toric lenses represent 23% of the $9 billion global contact lens market, presenting significant growth opportunities. Available in the U.S. and set for international rollout in February 2021, the lens aims to capture a market where 41% of patients are astigmatic but only 10% wear toric lenses.
Alcon (SIX/NYSE: ALC) has launched the AcrySof® IQ Vivity™ IOL, a first-of-its-kind non-diffractive extended depth of focus intraocular lens in the U.S., aimed at presbyopia patients undergoing cataract surgery. This innovative lens promises monofocal-quality distance vision with improved intermediate and near vision. With the U.S. cataract surgery market projected to reach 5.4 million by 2025, Vivity expands Alcon's IOL portfolio, enhancing patient options and experience. The lens is already available in several international markets.